S
Stephan A. Grupp
Researcher at Children's Hospital of Philadelphia
Publications - 396
Citations - 44427
Stephan A. Grupp is an academic researcher from Children's Hospital of Philadelphia. The author has contributed to research in topics: Chimeric antigen receptor & Transplantation. The author has an hindex of 77, co-authored 366 publications receiving 34450 citations. Previous affiliations of Stephan A. Grupp include University of Pennsylvania & St. Jude Children's Research Hospital.
Papers
More filters
Journal ArticleDOI
The MAGIC Algorithm Probability (MAP) Is a Validated Response Biomarker of Treatment for Acute Graft-Versus-Host Disease
Hrishikesh K. Srinagesh,Umut Ozbek,Urvi Kapoor,Francis Ayuk,Mina Aziz,Kaitlyn Ben-David,Hannah Choe,Zachariah DeFilipp,Aaron Etra,Stephan A. Grupp,Matthew J. Hartwell,Elizabeth O. Hexner,William J. Hogan,Alexander B. Karol,Stelios Kasikis,Carrie L. Kitko,Steven Kowalyk,Hannah Major-Monfried,Jung-Yi Lin,Stephan Mielke,Pietro Merli,George Morales,Rainer Ordemann,Michael A. Pulsipher,Muna Qayed,Pavan Reddy,Ran Reshef,Wolf Roesler,Karamjeet S. Sandhu,Tal Schechter,Jay Shah,Keith Sigel,Daniela Weber,Matthias Wölfl,Kitsada Wudhikarn,Rachel Young,John E. Levine,James L.M. Ferrara +37 more
TL;DR: The MAP is, to the authors' knowledge, the first laboratory test validated as a response biomarker for acute GVHD treatment and more accurately predicts survival than clinical response after 28 days of treatment.
Journal ArticleDOI
Efficacy and Safety of Humanized Chimeric Antigen Receptor (CAR)-Modified T Cells Targeting CD19 in Children with Relapsed/Refractory ALL
Shannon L. Maude,Shannon L. Maude,David M. Barrett,David M. Barrett,David E Ambrose,Susan R. Rheingold,Susan R. Rheingold,Richard Aplenc,Richard Aplenc,David T. Teachey,David T. Teachey,Colleen Callahan,Christine Barker,Maya Mudambi,Pamela A. Shaw,Jennifer Brogdon,Regina M. Young,John Scholler,Andreas Loew,Katherine T. Marcucci,Jeffrey Finklestein,Irina Kulikovskaya,Farzana Nazimuddin,Zhaohui Zheng,Bruce L. Levine,David L. Porter,Simon F. Lacey,J. Joseph Melenhorst,Carl H. June,Stephan A. Grupp,Stephan A. Grupp +30 more
TL;DR: It is hypothesized that repeat infusion may prolong persistence in some patients but would be ineffective in patients with immune-mediated rejection, and the safety and efficacy of CD19-directed CAR T cells with a humanized scFv domain in children with B cell recovery or CD19+ relapse after prior CAR T cell therapy is determined.
Journal ArticleDOI
Tacrolimus/Sirolimus Vs. Tacrolimus/Methotrexate for Graft-Vs.-Host Disease Prophylaxis After HLA-Matched, Related Donor Hematopoietic Stem Cell Transplantation: Results of Blood and Marrow Transplant Clinical Trials Network Trial 0402
Corey Cutler,Brent R. Logan,Ryotaro Nakamura,Laura Johnston,Sung Won Choi,David L. Porter,William J. Hogan,Marcelo C. Pasquini,Margaret L. MacMillan,John R. Wingard,Edmund K. Waller,Stephan A. Grupp,Philip L. McCarthy,Juan Wu,Zhen-Huan Hu,Shelly L. Carter,Mary M. Horowitz,Joseph H. Antin +17 more
TL;DR: Tac/Sir can be used as an alternative to Tac/Mtx in MRD HSCT, and is associated with more rapid engraftment, less severe acute GVHD and oral mucositis, excess chronic GV HD and endothelial injury syndromes, and similar long-term outcomes.
Journal ArticleDOI
T Cells Engineered with a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Have Long Term Persistence and Induce Durable Remissions in Children with Relapsed, Refractory ALL
Stephan A. Grupp,Stephan A. Grupp,Shannon L. Maude,Pamela A. Shaw,Richard Aplenc,David M. Barrett,Colleen Callahan,Anne Chew,Simon F. Lacey,Bruce L. Levine,J. Joseph Melenhorst,Laura S Motley,Susan R. Rheingold,Angela Shen,David T. Teachey,Patricia A. Wood,David L. Porter,Carl H. June +17 more
TL;DR: Results from the pilot trial in pediatric ALL showed that all responding pts developed grade 1-4 cytokine release syndrome (CRS) at peak T cell expansion, and detailed cytokine analysis showed marked increases of IL6 and IFNγ (both up to 1000x), and IL2R.
Journal ArticleDOI
Inhibition of tumor growth in a human neuroblastoma xenograft model with TNP-470
TL;DR: It is shown that TNP-470 is a potent inhibitor of human neuroblastoma growth both alone and when given with conventional chemotherapy, suggesting that it may be a useful adjunctive therapy for high-risk neuroblast cancer patients.